Previous 10 | Next 10 |
Innoviva (INVA): Q1 GAAP EPS of $0.84.Revenue of $85.52M (+8.7% Y/Y)Shares +1.8% AH.Press Release For further details see: Innoviva reports Q1 results
Royalties increased by 8% to $89.0 million in the first quarter of 2021, compared to the same quarter in 2020. Invested an additional $20.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP), an anti-infectives leader, in the first quarter of 2021. Deborah L. Birx, M.D., app...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Short review of IDNA. For further details see: Healthcare Dashboard For April And Focus On IDNA
It has been one year since the markets bottomed in March of 2020 due to COVID. Markets have rebounded beyond most investors’ expectations, with growth and tech stealing much of the spotlight. The “rotation into value” narrative has recently gained some tractio...
An arbitrator has ruled that Innoviva (INVA) did not breach an LLC agreement with Theravance Biopharma (TBPH) over royalties related to sales of GlaxoSmithKline's (GSK) asthma inhaler Trelegy.The LLC, Theravance Respiratory Company ("TRC"), was established when the former Thervance (prio...
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, may face further pressure from another activist fund Sarissa Capital Management.Sarissa, led by Alex Denner, who at one time worked for Carl Icahn, is the biggest hedge fund owner of Alker...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Focus on XBI. For further details see: Healthcare Dashboard For March And Focus On XBI
Armata Pharmaceuticals (ARMP) has completed the closing of the second and final tranche of the company's $20M private placement with Innoviva Strategic Opportunities, a wholly-owned subsidiary of Innoviva (INVA).In connection with the second closing, Armata issued 4.29M shares and 4.29M warra...
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva PR Newswire MARINA DEL REY, Calif. , March 17, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Compa...
On March 09, 2021, Innoviva (INVA) has appointed Deborah L. Birx as an independent director of the board.A medical graduate from the Hershey School of Medicine, Pennsylvania State University Dr. Birx previously served as the response coordinator of the White House Coronavirus Task F...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...